Linda Narvaez, MD
Family Medicine · Culver City, CANPI 1588760508
Payments from drug & device makers
Across 347 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$1K
- Novo Nordisk$887
- AstraZeneca$625
- Takeda Pharmaceuticals U.S.A., Inc.$425
- Lilly USA, LLC$356
- plus $2K from 32 others
What the payments were for
- Food & beverage$7,870100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $2,069 |
| Gilead | 52 | $1,283 |
| Novo Nordisk | 47 | $887 |
| AstraZeneca(2 entities) | 16 | $625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $425 |
| Lilly USA, LLC | 16 | $356 |
| Bayer | 16 | $316 |
| Idorsia Pharmaceuticals US Inc | 5 | $204 |
| Boehringer Ingelheim | 8 | $179 |
| Amgen | 7 | $163 |
| GSK | 6 | $146 |
| Ultragenyx Pharmaceutical Inc. | 6 | $128 |
| Exact Sciences | 6 | $121 |
| IBSA Pharma Inc. | 6 | $112 |
| Biohaven Pharmaceuticals, Inc. | 4 | $88 |
| Upsher-smith Laboratories LLC | 3 | $63 |
| Nestle Healthcare Nutrition Inc. | 2 | $61 |
| Organon | 2 | $56 |
| Boston Scientific | 2 | $53 |
| Medline Industries LP | 1 | $53 |
| Genentech USA, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Sanofi | 1 | $38 |
| Nevro Corp. | 2 | $36 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Tandem Diabetes Care, Inc. | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $20 |
| Tolmar, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,870 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $34,376 |
| FarxigaDapagliflozin Propanediol | 26 | $28,840 |
| JardianceEmpagliflozin | 16 | $12,344 |
| Bupropion XlBupropion Hcl | 12 | $4,457 |
| Repaglinide | 35 | $1,537 |
| Estradiol | 21 | $1,188 |
| Rosuvastatin Calcium | 64 | $1,105 |
| Potassium Chloride | 14 | $1,039 |
| Atorvastatin Calcium | 63 | $807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $698 |
| Levothyroxine Sodium | 50 | $631 |
| Zolpidem Tartrate ErZolpidem Tartrate | 21 | $599 |
| Gabapentin | 15 | $596 |
| Pantoprazole Sodium | 33 | $486 |
| SynthroidLevothyroxine Sodium | 11 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $887 | $34,37637 claims |
| AstraZenecaFarxiga | $625 | $28,84026 claims |
| Boehringer IngelheimJardiance | $179 | $12,34416 claims |
| AbbVieSynthroid | $2,069 | $47211 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $14 | $14219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Culver City
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.